Literature DB >> 28077689

Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.

Lin Li1, Tuhina Neogi2, Susan Jick1.   

Abstract

Objective: To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients.
Methods: Using the UK-based Clinical Practice Research Datalink we identified 9778 newly diagnosed GCA patients in 1990-2014, and up to 10 non-vasculitis patients randomly matched to each case on age, sex, practice and years of history before cohort entry. We compared the distributions of 9 different pre-existing vascular diseases and 11 other comorbidities, and risks of incident vascular diseases and other comorbidities after cohort entry between GCA and non-vasculitis patients.
Results: Patients with GCA were more likely to have a history of vascular diseases and other comorbidities except myocardial infarction, type 2 diabetes, obesity and cancer, compared with non-vasculitis patients. Patients with GCA had increased risks for all types of incident vascular disease compared with non-vasculitis patients: adjusted hazard ratios were 1.57 (95% CI: 1.36, 1.82) for myocardial infarction, 1.41 (95% CI: 1.29, 1.55) for stroke, 1.75 (95% CI: 1.49, 2.06) for peripheral vascular disease, 1.98 (95% CI: 1.50, 2.62) for aortic aneurysm and 2.03 (95% CI: 1.77, 2.33) for venous thromboembolism. Patients with GCA also had increased risks for other incident comorbidities (type 2 diabetes, depression, etc.), but not for cancer.
Conclusion: Patients with GCA had more prior vascular diseases and other comorbidities before the diagnosis and they also had increased risks for incident vascular diseases and many other incident comorbidities after the diagnosis compared with non-vasculitis population.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Clinical Practice Research Datalink; cohort.; comorbidity; giant cell arteritis; myocardial infarction; stroke; type 2 diabetes; vascular disease; vasculitis; venous thromboembolism

Mesh:

Year:  2017        PMID: 28077689     DOI: 10.1093/rheumatology/kew482

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

1.  Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study.

Authors:  Max Yates; Robert Luben; Shabina Hayat; Sarah L Mackie; Richard A Watts; Kay-Tee Khaw; Nick J Wareham; Alex J MacGregor
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

Review 2.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

Review 3.  Looking ahead: giant-cell arteritis in 10 years time.

Authors:  Milena Bond; Alessandro Tomelleri; Frank Buttgereit; Eric L Matteson; Christian Dejaco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

Review 4.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

5.  Glucose metabolism controls disease-specific signatures of macrophage effector functions.

Authors:  Ryu Watanabe; Marc Hilhorst; Hui Zhang; Markus Zeisbrich; Gerald J Berry; Barbara B Wallis; David G Harrison; John C Giacomini; Jörg J Goronzy; Cornelia M Weyand
Journal:  JCI Insight       Date:  2018-10-18

6.  Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.

Authors:  Lana Yin Hui Lai; Emma Harris; Robert M West; Sarah Louise Mackie
Journal:  RMD Open       Date:  2018-02-28

7.  The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis.

Authors:  Bradley Pittam; Sonal Gupta; Ashar E Ahmed; David M Hughes; Sizheng Steven Zhao
Journal:  Rheumatol Int       Date:  2020-06-04       Impact factor: 2.631

8.  Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; B-T S Fevang; A P Diamantopoulos; J Assmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2019-06-25       Impact factor: 5.156

9.  Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen.

Authors:  Chetan Mukhtyar; Heidi Cate; Conor Graham; Peter Merry; Karen Mills; Aseema Misra; Colin Jones
Journal:  Rheumatol Adv Pract       Date:  2019-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.